Status:
UNKNOWN
Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy
Lead Sponsor:
Mahidol University
Conditions:
Antiemetic for Highly Emetogenic Chemotherapy
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant based on previ...
Detailed Description
Aprepitant and olanzapine have been recommended for emesis prevention from highly emetogenic chemotherapy. We hypothesized that olanzapine may lead to less nausea compared to aprepitant based on previ...
Eligibility Criteria
Inclusion
- pathologically proved of solid malignancy
- receive first cycle of cisplatin \>= 50 mg/m2 or cyclophosphamide/doxorubicin
Exclusion
- pregnancy
- patients with episode of vomiting within 24 hours before starting chemotherapy
- uncontrolled brain/ CNS metastasis
- gut obstruction
- receive combination of moderate or high emetogenic chemotherapy during Day 2-5
- Known allergy to ondansetron, olanzapine, aprepitant or dexamethasone
- currently receive olanzapine with other indication and plan to continue the drug
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
147 Patients enrolled
Trial Details
Trial ID
NCT03876938
Start Date
March 1 2019
End Date
December 1 2020
Last Update
March 15 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of medical oncology, department of medicine Siriraj Hospital
Bangkok, Thailand, 10700
2
Siriraj Hospital
Bangkok, Thailand, 10700